Important Safety Information
Please review this important safety information carefully before starting any treatment plan. This page is not a substitute for medical advice from your licensed healthcare provider.
About FlatRx
FlatRx is a telehealth platform that connects patients with licensed, independent healthcare providers. FlatRx does not provide medical advice, diagnose conditions, prescribe, compound or dispense medication. FlatRx is not a pharmacy and is not licensed as a medical provider. All treatment decisions are made solely by licensed providers based on individual clinical evaluation.
About compounded medications
FlatRx plans are only for compounded semaglutide and compounded tirzepatide, prepared by US-licensed 503A compounding pharmacies based on a valid prescription from an independent licensed provider.
Important: Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or manufacturing quality. They are not therapeutically equivalent to FDA-approved medications. A licensed provider prescribes a compounded medication only if they determine, after reviewing your online visit, that it is appropriate for you.
Compounded semaglutide and compounded tirzepatide on FlatRx plans currently contain an additional ingredient, even if you choose no preference in your online visit. The dispensed formulation is named on your pharmacy label, and your provider decides whether to prescribe it. Tell your provider about any allergies to medication ingredients, and ask your provider which additional ingredient is in your medication.
Boxed warning: thyroid C-cell tumors
WARNING: RISK OF THYROID C-CELL TUMORS
In animal studies, GLP-1 receptor agonist medications caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether GLP-1 receptor agonists, including compounded semaglutide and compounded tirzepatide, cause thyroid C-cell tumors, including MTC, in humans. GLP-1 receptor agonist medications are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Tell your healthcare provider immediately if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid tumors. If medullary thyroid carcinoma is suspected, your provider will discontinue your treatment and refer you for further evaluation.
Compounded semaglutide: safety information
Compounded semaglutide is a GLP-1 receptor agonist medication. The information below is adapted from the prescribing information for FDA-approved GLP-1 receptor agonist medications. Compounded semaglutide is not FDA-approved, has not been evaluated by the FDA for safety, effectiveness or quality, and is not therapeutically equivalent to any FDA-approved product; its risks may differ. Follow these precautions and ask your provider about your own risks.
Contraindications
Do not use compounded semaglutide if you have:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A known hypersensitivity to compounded semaglutide or any of its ingredients
Warnings and precautions
Tell your healthcare provider before starting treatment if you have or have had:
- Pancreatitis or a history of pancreatitis
- Kidney problems or kidney disease
- Diabetic retinopathy (if you have type 2 diabetes)
- Gallbladder problems
- Depression, suicidal thoughts, or mental health conditions
- Allergic reactions to any GLP-1 receptor agonist
- A planned surgery or procedure with anesthesia or deep sedation (tell your provider and the procedure team that you take this medication, because of a risk of pulmonary aspiration)
Common side effects
The most common side effects include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Decreased appetite
- Dizziness
- Injection site reactions
Most side effects are mild to moderate and tend to improve over time as your body adjusts to the medication. Side effects are often most pronounced during dose escalation.
Serious side effects
Seek immediate medical attention if you experience:
- Signs of thyroid tumors: A lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath
- Pancreatitis: Severe, persistent abdominal pain that may radiate to the back, with or without vomiting
- Allergic reactions: Swelling of the face, lips, tongue, or throat; difficulty breathing; rapid heartbeat; rash or itching
- Hypoglycemia: Dizziness, blurred vision, anxiety, irritability, sweating, slurred speech, or confusion — especially if taking insulin or sulfonylureas
- Kidney injury: Changes in urination, swelling in legs or ankles
- Gallbladder problems: Upper stomach pain, fever, clay-colored stools, yellowing of skin or eyes (jaundice)
Drug interactions
Compounded semaglutide may interact with other medications. Tell your provider about all medications you are taking, including:
- Insulin or sulfonylureas: Risk of hypoglycemia may increase; dose adjustments may be needed
- Oral medications: GLP-1 receptor agonist medications slow gastric emptying, and compounded semaglutide may do the same, which may affect the absorption of oral medications. Discuss timing of doses with your provider
- Warfarin or other anticoagulants: Monitor INR more frequently when starting or changing your compounded semaglutide dose
The above safety information is provided for educational purposes and does not cover all possible uses, warnings, precautions, drug interactions, or adverse effects. This information has not been evaluated by the Food and Drug Administration. Compounded semaglutide is not FDA-approved. Consult your licensed healthcare provider for complete information.
Compounded tirzepatide: safety information
Compounded tirzepatide is a dual GIP and GLP-1 receptor agonist medication. The information below is adapted from the prescribing information for FDA-approved GIP and GLP-1 receptor agonist medications. Compounded tirzepatide is not FDA-approved, has not been evaluated by the FDA for safety, effectiveness or quality, and is not therapeutically equivalent to any FDA-approved product; its risks may differ. Follow these precautions and ask your provider about your own risks.
Contraindications
Do not use compounded tirzepatide if you have:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A known hypersensitivity to compounded tirzepatide or any of its ingredients
Warnings and precautions
Tell your healthcare provider before starting treatment if you have or have had:
- Pancreatitis or a history of pancreatitis
- Kidney problems or kidney disease
- Type 1 diabetes
- Diabetic retinopathy
- Gallbladder problems
- Severe gastrointestinal disease
- Depression, suicidal thoughts, or mental health conditions
- A planned surgery or procedure with anesthesia or deep sedation (tell your provider and the procedure team that you take this medication, because of a risk of pulmonary aspiration)
Common side effects
The most common side effects include:
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Abdominal pain
- Indigestion (dyspepsia)
- Injection site reactions
- Fatigue
- Heartburn (gastroesophageal reflux)
- Belching
- Hair loss
Most side effects are mild to moderate and tend to improve over time as your body adjusts to the medication. Side effects are often most pronounced during dose escalation.
Serious side effects
Seek immediate medical attention if you experience:
- Signs of thyroid tumors: A lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath
- Pancreatitis: Severe, persistent abdominal pain that may radiate to the back, with or without vomiting
- Allergic reactions: Swelling of the face, lips, tongue, or throat; difficulty breathing; severe rash; rapid heartbeat
- Hypoglycemia: Dizziness, blurred vision, anxiety, sweating, slurred speech, or confusion — especially if taking insulin or sulfonylureas
- Kidney injury: Decreased urination, swelling in legs or ankles, fatigue
- Gallbladder problems: Upper stomach pain, fever, clay-colored stools, yellowing of skin or eyes (jaundice)
- Severe gastrointestinal reactions: Persistent, severe nausea, vomiting, or diarrhea leading to dehydration
Drug interactions
Compounded tirzepatide may interact with other medications. Tell your provider about all medications you are taking, including:
- Insulin or sulfonylureas: Risk of hypoglycemia may increase; dose adjustments may be needed
- Oral medications: GLP-1 receptor agonist medications slow gastric emptying, and compounded tirzepatide may do the same, which may affect the absorption of oral medications. This is particularly important for medications with a narrow therapeutic window. Discuss timing with your provider
- Oral hormonal contraceptives: Effectiveness may be reduced due to delayed gastric emptying. Use a non-oral backup contraceptive method for 4 weeks after initiation and for 4 weeks after each dose escalation
The above safety information is provided for educational purposes and does not cover all possible uses, warnings, precautions, drug interactions, or adverse effects. This information has not been evaluated by the Food and Drug Administration. Compounded tirzepatide is not FDA-approved. Consult your licensed healthcare provider for complete information.
Pregnancy and breastfeeding
Do not use GLP-1 receptor agonist medications if you are pregnant, plan to become pregnant, or are breastfeeding.
- Animal studies have shown that GLP-1 receptor agonists may cause harm to a developing fetus. There is insufficient data in humans to determine the risk during pregnancy.
- Discontinue treatment at least 2 months before a planned pregnancy due to the long half-life of these medications. Notify your provider immediately if you become pregnant during treatment.
- It is not known whether compounded semaglutide or compounded tirzepatide passes into breast milk. Due to the potential for adverse effects in a nursing infant, breastfeeding is not recommended during treatment.
- If you are of childbearing potential, discuss appropriate contraceptive methods with your provider before starting treatment.
Storage and handling
- Follow the storage instructions and beyond-use date on your pharmacy label. Unless your label says otherwise, keep your medication refrigerated at 36°F to 46°F (2°C to 8°C) before and after first use. Do not freeze it, and do not use it if it has been frozen or kept out of the refrigerator longer than your label allows.
- Protect from light and excessive heat.
- Do not use if the solution is discolored, cloudy, or contains particles.
- Keep out of the reach of children.
- Dispose of needles and syringes in an FDA-cleared sharps container. Do not dispose of loose needles in household trash.
When to contact your provider
Contact your provider if you experience:
- Side effects that are severe, persistent, or worsening
- New or unusual symptoms after starting or changing a dose
- Difficulty administering your medication
- Questions about drug interactions with new medications
- Changes in your health status or medical history
For medical emergencies, call 911 immediately. Do not wait to contact your provider in an emergency.
How to report side effects
Tell your provider right away if you experience side effects. Message your provider through the FlatRx patient portal; for emergencies call 911.
You can also report side effects to the dispensing pharmacy using the contact details on your pharmacy label.
Report serious side effects to FDA MedWatch, online at www.fda.gov/medwatch or by phone at 1-800-FDA-1088 (1-800-332-1088).
For help reaching your provider, email support@flatrx.io.
Consult your provider
This page is provided for informational purposes only and does not constitute medical advice. It does not cover all possible uses, warnings, precautions, drug interactions, or adverse effects. Always consult with your licensed healthcare provider before starting, stopping, or changing any treatment. Your provider will review your complete medical history and current medications to determine if a treatment plan is appropriate for you.